Likelihood of Approval and Phase Transition Success Rate Model – Erdafitinib in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Powered by
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Erdafitinib in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.
Erdafitinib in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Drug Details:
Erdafitinib (Balversa, Erfandel) is an alkyldiarylamine compound acts as an antineoplastic agent. It is formulated as film coated tablets for oral route of administration. Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) that has susceptible FGFR3 or FGFR2 genetic alterations, and progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.Erdafitinib (JNJ-42756493) is under development for the treatment of metastatic or surgically unresectable urothelial cancer (second line therapy), high-grade glioma, duodenal cancer, thyroid cancer, salivary gland cancer, endometrial cancer, colorectal cancer, pancreatic cancer, refractory solid tumors and lymphomas including squamous and non-squamous non-small cell lung cancer, relapsed/ refractory multiple myeloma, small cell lung cancer, advanced hepatocellular carcinoma (HCC), breast cancer, ovarian cancer, prostate cancer, lung adenocarcinoma, head and neck cancer, esophageal cancer, cholangiocarcinoma, non muscle invasive bladder cancer (NMIBC), muscle invasive bladder cancer (MIBC), glioblastoma multiforme and gastric cancer. The drug candidate is administered orally. It is a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor and is based on fragment-based pyramid platform. It is a new molecular entity (NME).
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
Quick View – Erdafitinib LOA Data | |||||
Report Segments |
|
||||
Drug Name |
|
||||
Administration Pathway |
|
||||
Therapeutic Areas |
|
||||
Key Manufacturers |
|
||||
Drug Development Status |
|
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Frequently asked questions
- Drugs which have been approved in the past 10 years
- Drugs which have failed during clinical development in the past 18 years
- Drugs which are currently in development
- Phase I, Phase II, Phase III, and Pre-Registration development stage
- Drugs must meet one of the following criteria to be included in the model:
- The developer has specified the US as an intended market for approval.
- The developer has not specified any country as an intended market for approval, i.e. the “Drug Geography” is listed as “Global”
- Innovator drugs and biosimilars
- Diagnostics, Imaging Agents, Biomarkers, stents and other drug delivery devices (covered in GlobalData’s Medical Intelligence Center).
- Nutraceuticals, dietary supplements, alternative medicines, imaging agents, radio emitter, transplants, transfusions, fillers, cosmetics, probiotics, antiseptics, antacids, mobilizing agents, veterinary drugs and drugs not seeking approval.
- Generic drugs
- Innovative drugs in Preclinical or Discovery Stage.
- Pipeline drugs sponsored by a Government or Institution.
- Drugs with a specific Drug Geography not the United States.
The probability of a drug ultimately receiving market authorization
The probability of a drug’s advancement to the next stage of clinical development
GlobalData’s Drug-Specific Likelihood of Approval (LoA) calculates the Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) customized to individual drug. The model uses a combination of Machine Learning (ML) and a GlobalData proprietary algorithm to process data points from the Drugs, Clinical Trials, Regulatory Milestones, Company, and Financial databases.
Inclusion
Data Scope:
Drug Phase Scope:
Drug Geography Scope:
Drug Type Scope:
Entity Type Scope:
Only drugs in development by companies are included in the model.
Exclusion
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745